Abstract
To determine the value of specific immunotherapy with adjuvant BCG in operable lung cancer, the immunological and clinical results of serial postoperative injections of autologous irradiated tumour cells and BCG were compared with those of a single preoperative injection of BCG in two randomly selected groups of patients undergoing resection of their tumours. There was a significant rise in tuberculin skin reactivity from seven weeks to 11 months after operation in the treated group. Actuarial curves for survival and freedom from tumour recurrence and median survival times showed an advantage for the treated patients who had stage I tumours, but these differences were significant only at the levels p = 0.07 - 0.09. Survival and duration of freedom from tumour recurrence was greater in autograft-treated patients whose skin responded to a weak test dose of dinitrochlorobenzene (DNCB) after sensitisation with 2% DNCB than in control DNCB-positive patients (p = 0.02). There were no significant differences in the actual proportion of patients from each group surviving at two years. The results show that this form of specific immunotherapy with adjuvant may have a beneficial effect in patients with stage I tumours and those who become sensitised to 2% DNCB after the first exposure.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Edwards F. R., Whitwell F. Use of BCG as an immunostimulant in the surgical treatment of carcinoma of lung: a five-year follow-up report. Thorax. 1978 Apr;33(2):250–252. doi: 10.1136/thx.33.2.250. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Evans D. A. Immunology of bronchial carcinoma. Thorax. 1976 Oct;31(5):493–506. doi: 10.1136/thx.31.5.493. [DOI] [PMC free article] [PubMed] [Google Scholar]
- McKneally M. F., Maver C., Kausel H. W. Regional immunotherapy of lung cancer with intrapleural B.C.G. Lancet. 1976 Feb 21;1(7956):377–379. doi: 10.1016/s0140-6736(76)90212-9. [DOI] [PubMed] [Google Scholar]
- Millar J. W., Roscoe P., Pearce S. J., Ludgate S., Horne N. W. Five-year results of a controlled study of BCG immunotherapy after surgical resection in bronchogenic carcinoma. Thorax. 1982 Jan;37(1):57–60. doi: 10.1136/thx.37.1.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Perlin E., Oldham R. K., Weese J. L., Heim W., Reid J., Mills M., Miller C., Blom J., Green D., Bellinger S., Jr Carcinoma of the lung: immunotherapy with intradermal BCG and allogeneic tumor cells. Int J Radiat Oncol Biol Phys. 1980 Aug;6(8):1033–1039. doi: 10.1016/0360-3016(80)90113-3. [DOI] [PubMed] [Google Scholar]
- Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Smith R. A. Long-term clinical follow-up after operation for lung carcinoma. Thorax. 1970 Jan;25(1):62–76. doi: 10.1136/thx.25.1.62. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Soorae A. S., Stevenson H. M. Survival with residual tumor on the bronchial margin after resection for bronchogenic carcinoma. J Thorac Cardiovasc Surg. 1979 Aug;78(2):175–180. [PubMed] [Google Scholar]
- Stack B. H., McSwan N., Stirling J. M., Hole D. J., Parratt D., Spilg W. G., Gillis C. R., McHattie I., Green A. G., White R. G. Cell-mediated immunity in operable bronchial carcinoma: the effect of injecting irradiated autologous tumour cells and BCG. Thorax. 1979 Feb;34(1):68–73. doi: 10.1136/thx.34.1.68. [DOI] [PMC free article] [PubMed] [Google Scholar]